Our mission
To transform the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
Our vision
Patients with rare neuroendocrine diseases are able to live their fullest lives and are transformed through optimal, stigma-free care.
It takes great people to make a great company
It’s the people that make Rhythm so special.
Our path to transforming the care of rare melanocortin-4 receptor (MC4R) pathway diseases
Our story
Rhythm was founded in 2008 in Boston.
Our lead asset, IMCIVREE® (setmelanotide), FDA-approved in 2020, is a precision medicine designed to treat severe obesity caused by an impairment of a pathway in the hypothalamus called the MC4R pathway.
Rhythm became a publicly traded company in 2017. Now, we have grown to more than 250 employees in North America and Europe. With a robust clinical trials program, we remain poised for even more growth in the near future. As we continue to grow, the one thing that will never change is our commitment to patients.
Our leadership team is passionate about developing new therapies for patients.
Our employees strive every day to pioneer a path forward for patients and families living with rare neuroendocrine diseases.